When will the patents on BENTYL expire, and when will generic BENTYL be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	BENTYL	dicyclomine hydrochloride	CAPSULE;ORAL	007409-003	Oct 15, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Allergan	BENTYL	dicyclomine hydrochloride	TABLET;ORAL	007409-001	Oct 15, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Abbvie	BENTYL	dicyclomine hydrochloride	INJECTABLE;INJECTION	008370-001	Oct 15, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 23, 2026

Bentyl (dicyclomine) Investment Scenario and Fundamentals Analysis: Patent, Exclusivity, Generic Risk, and Commercial Outlook

Bentyl is an established, off-patent antispasmodic brand based on dicyclomine hydrochloride. For investment purposes, the fundamental question is not “is there patent protection,” but “how fast does generic competition compress net pricing and volume share,” and “is there any differentiated safety/labeling or dosage-form moat versus cost-only suppliers.”

What is Bentyl (dicyclomine) used for and what does its payer profile look like?

Therapeutic role: Bentyl (dicyclomine) is used for symptomatic treatment of irritable bowel syndrome (IBS) and other GI spasm-related indications under US labeling frameworks. It is marketed in oral dosage forms (historically tablets and capsules; also historically liquid presentations in some markets).

Demand characteristics:

Chronic/recurring use (IBS symptom control) supports repeat prescriptions.
Low switching cost for prescribers and patients once generics are available, because the active ingredient is the same.
Insurance-driven access: in most formularies, dicyclomine generics are positioned as tier 1-2, with brand reserve use limited to intolerance, prior authorization carve-outs, or plan-specific contracting.

Investment implication: The drug is a generic-competition case study, where returns depend on (1) share retention through contracting, (2) manufacturing and distribution efficiency, and (3) any remaining exclusivity tied to specific dosage forms or NDCs, not the molecule itself.

What is the Orange Book status of Bentyl, and which patents still matter?

Answer (high level): Bentyl is widely treated as commercially off-patent for the active ingredient. The actionable patent risk for investors is typically confined to:

Formulation or manufacturing patents tied to specific NDCs/dosage forms
Method-of-use patents that may cover particular labeled regimens (rare at this age)
Any remaining pediatric/marketing exclusivity or orphan-type exclusivity (Bentyl is not orphan)
Oral liquid concentration or stable formulation IP (where applicable)

Practical takeaway: For an investment scenario built on royalties or licensing economics, the patent estate is usually insufficient to block full generic entry across the segment. The economics skew toward contracting and channel execution rather than IP-driven pricing power.

When does Bentyl lose exclusivity, and what does that mean for launch timing?

Answer (high level): Exclusivity windows for the original brand product have long since run out. In the US, the main remaining events would have been:

Patent expirations (composition, method, formulation)
Any supplementary exclusivity (generally limited for older small molecules)
Generics market entry through ANDA referencing the branded NDA

Timing implication: Even absent exact Orange Book dates in the public record within this prompt, the commercial reality for an investor is that Bentyl’s molecule has already passed through the generic waves. The “when” question largely maps to NDC-level availability and contracting cycles, not to a new exclusivity cliff.

What patents protect dicyclomine products like Bentyl, and how strong is the estate?

Answer (high level): For dicyclomine, the original IP has largely expired, and the remaining estate, when present, is typically:

Formulation patents (polymorphs are uncommon for small-molecule salts but process-based stability patents do appear)
Manufacturing process patents (granulation, coating, compression processes, stability in packaging)
Method-of-use patents (often weak at this stage unless tied to a specific treatment definition)

Investment implication: The strength of any remaining patent estate is usually narrow in scope. That means:

Generic entrants can often design around formulation/method claims.
Litigation, if any, is more likely to be NDC-specific than a broad block on “dicyclomine” generally.

How many generics compete with Bentyl, and what pricing pressure should investors expect?

Answer (high level): Dicyclomine is a widely distributed, low-cost generic platform. The expected pattern is:

Rapid net price erosion following ANDA launches
Multiple suppliers per dosage form/NDC
Tiering on formularies that limits brand share
PBM contracting pressure that pushes dispensing toward the cheapest or preferred generic

Investment implication: A Bentyl-centered investment thesis must underwrite:

sustainable margins despite commoditization
logistics and fill-rate advantages
potential portfolio offsets (other differentiated products) if Bentyl is only a small slice

What generic entry risks exist for Bentyl, including Paragraph IV challenges?

Answer (high level): Paragraph IV challenges apply only if there are still Orange Book-listed patents with respect to referenced NDA. Given Bentyl’s age and broad generic availability, the highest practical risk is not a new Paragraph IV event. It is:

additional NDC-level competitors
shifts in preferred product selection during PBM bid cycles
supply shocks that can create temporary pricing spikes but not durable moat

Investment implication: The risk profile behaves like a commodity rather than a “binary” IP event.

What biosimilar risk applies to Bentyl?

Answer: None. Bentyl is a small-molecule drug. Biosimilars are not relevant.

What formulations are protected for Bentyl and which dosage forms matter commercially?

Answer (high level): Commercial moat, if any, is typically tied to:

oral tablet/capsule specific manufacturing and stability
oral solution concentration and packaging stability (where available in US market and specific NDCs)
release profile: dicyclomine is generally not a complex controlled-release molecule, so “release technology” moat is limited versus extended-release platforms

Investment implication: Investors should treat dosage-form differentiation as:

an operational and manufacturing excellence question
not a durable IP umbrella unless a specific process is still protected and enforceable

Which companies market Bentyl or dicyclomine generics, and how does the competitive landscape affect margins?

Answer (high level): The landscape is dominated by generic manufacturers that compete through:

contracting with wholesalers and PBMs
manufacturing scale and compliance quality
NDC-specific supply and distribution agreements

Investment implication: Margin sustainability depends more on:

cost position (API and excipient sourcing)
plant capacity utilization
ability to maintain stable supply without recall-driven share loss than on patent strategy.

What patent litigation affects Bentyl, and what does it mean for investors?

Answer (high level): For older, widely generic small molecules, litigation is usually:

isolated
NDC-specific
time-limited

Investment implication: In a Bentyl-centric case, litigation rarely drives long-term returns unless it produces:

an enforceable injunction for a differentiated formulation
a licensing settlement that preserves pricing beyond the next generic wave

Without a current, specific litigation docket tied to a relevant NDC or formulation (not provided in this prompt), the investment-grade conclusion is that litigation is not the primary driver of forward economics.

Is Bentyl on the FDA market as of today, and what pathway governs new entrants?

Answer (high level):

New entrants use ANDA for generic dicyclomine products.
The reference listed drug is dicyclomine on the branded NDA.

Investment implication: The regulatory barrier is mainly:

bioequivalence compliance
chemistry, manufacturing, controls (CMC)
labeling conformance rather than novel clinical development risk.

How does Bentyl compare with other antispasmodics for IBS/functional GI disorders in IP and economics?

Competitive class comparison (investment-relevant):

Other IBS antispasmodic approaches compete through label positioning and side effect profile, not patent-exclusive efficacy.
Most class competitors are also subject to generic entry, so the market tends to reward:
- lowest-cost access through formularies
- stable supply
- minimal recall and compliance incidents

Investment implication: If Bentyl’s molecule is commoditized, class-level strategy matters:

portfolio selection across antispasmodics and GI symptom products
manufacturing advantage across multiple SKUs to offset margin compression

Commercial fundamentals: what revenue and volume drivers matter most for a Bentyl investment thesis?

Key drivers (what moves P&L):

NDC mix (tablets/capsules vs any solution forms)
Wholesale and PBM contracting (preferred lists and bid outcomes)
Gross-to-net pressure (rebates, chargebacks, discounts)
Manufacturing yield and recall risk (compliance events are financially material)
Supply continuity (stock-outs can permanently shift prescriber behavior to preferred generics)
Working capital and inventory turns (commodity pharma economics)

Investment implication: For an older generic brand, the best leading indicators are channel-level:

bid outcomes
preferred brand-to-generic share shifts
NDC-level pricing trend versus key generic competitors

What are the best-case and base-case generic price compression scenarios for Bentyl?

Base-case behavior for established generic small molecules:

After multiple generic entries, net pricing tends toward a low, competitive range.
New entrants generally compete for share rather than sustaining premium pricing.

Best-case scenario requires at least one constraint:

continued brand or branded-generic contracting strength on specific formularies
NDC-level supply constraint among competing generics
manufacturing disruptions that temporarily favor remaining suppliers

Investment implication: A realistic Bentyl view should treat price as highly path-dependent on contracting, not on IP.

What would an attractive investment structure look like for Bentyl exposure?

Structuring lenses:

Margin-through-operations: scale manufacturing and contracting discipline
Portfolio hedge: combine Bentyl with higher-value differentiated assets (if available)
Channel intelligence: monitor PBM bid cycles and preferred supplier status
NDC strategy: focus on SKUs with best contribution margin and lowest competitive intensity

Not investment-grade without specific rights: Any strategy built solely on patents, injunctions, or exclusivity is typically mispriced for an older dicyclomine platform.

Key Takeaways

Bentyl (dicyclomine) is an established antispasmodic with economics dominated by generic competition.
The actionable IP question is usually NDC-level formulation or process protection, not broad molecule exclusivity.
Investment returns depend primarily on contracting, channel access, manufacturing efficiency, and supply continuity, not on new exclusivity events.
Generic entry risk is best characterized as ongoing competitive share pressure, not a single Paragraph IV cliff.
Biosimilar risk does not apply.

FAQs

1) Is Bentyl a generic drug or a brand-only product in the US market?
Bentyl is a branded product, but dicyclomine is available widely as generics; most of the market is generic-driven.

2) Can a generic manufacturer challenge Bentyl patents via ANDA Paragraph IV?
Only if relevant Orange Book patents are still listed for the referenced NDA and are not expired; for older products, the practical risk is typically incremental NDC competition rather than a new blocking event.

3) What is the biggest risk for a supplier competing with Bentyl?
PBM/wholesale contracting shifts and net price compression driven by low-cost generic preferred access.

4) Are there any biosimilar substitutes for Bentyl?
No. Bentyl is a small molecule.

5) What dosage form of Bentyl is most relevant for profitability?
The most profitable NDC is the one with the best contribution margin after net-price adjustments, typically driven by contracting and competitive intensity for that specific form.

References (APA)

US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
FDA. ANDA (Abbreviated New Drug Application) Overview. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
FDA. Drug Safety and Labeling Information for Prescription Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

BENTYL Drug Patent Profile

Which patents cover Bentyl, and when can generic versions of Bentyl launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bentyl

AI Deep Research

Questions you can ask:

Summary for BENTYL

US Patents and Regulatory Information for BENTYL